• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Buller Richard E gifted 500 shares, exercised 3,900 shares at a strike of $14.83 and sold $377,255 worth of shares (3,900 units at $96.73) (SEC Form 4)

    11/21/25 4:14:32 PM ET
    $CELC
    Medical Specialities
    Health Care
    Get the next $CELC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Buller Richard E

    (Last) (First) (Middle)
    16305 36TH AVE N
    SUITE 100

    (Street)
    MINNEAPOLIS MN 55446

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Celcuity Inc. [ CELC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/19/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/19/2025 G 500 D $0 7,260 I By Trust(1)
    Common Stock 11/20/2025 M 3,900 A $14.83 11,160 I By Trust(1)
    Common Stock 11/20/2025 S 3,900 D $96.732(2) 7,260 I By Trust(1)
    Common Stock 1,029 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $14.83 11/20/2025 M 3,900 (3) 06/04/2034 Common Stock 3,900 $0 2,622 I By Trust(1)
    Explanation of Responses:
    1. The Reporting Person and his spouse are the trustees and beneficiaries. The Reporting Person continues to beneficially own these securities held by the trust.
    2. The price reported in Column 4 is a weighted average price. These shares of common stock of the issuer were traded in multiple transactions at prices ranging from $96.465 to $96.920, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
    3. 100% vested.
    /s/ Griffin D. Foster as Attorney-in-Fact for Richard E. Buller pursuant to Power of Attorney previously filed 11/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CELC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CELC

    DatePrice TargetRatingAnalyst
    11/18/2025$110.00Outperform
    Wolfe Research
    11/17/2025Buy → Neutral
    H.C. Wainwright
    9/22/2025$110.00Buy
    Guggenheim
    7/1/2025$30.00Buy
    Stifel
    7/22/2024$29.00Outperform
    Leerink Partners
    2/22/2024$40.00Buy
    Stifel
    12/8/2023$27.00Buy
    H.C. Wainwright
    10/8/2021$50.00Buy
    Canaccord Genuity
    More analyst ratings

    $CELC
    SEC Filings

    View All

    SEC Form 144 filed by Celcuity Inc.

    144 - Celcuity Inc. (0001603454) (Subject)

    11/21/25 1:41:46 PM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Celcuity Inc. (0001603454) (Filer)

    11/17/25 4:36:18 PM ET
    $CELC
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Celcuity Inc.

    SCHEDULE 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/25 4:06:01 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

    MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for gedatolisib in hormone receptor positive ("HR+"), human epidermal growth factor receptor 2 negative ("HER2-"), advanced breast cancer ("ABC"). The NDA was submitted under the FDA's Real-Time Oncology Review ("RTOR") program, which is intended to facilitate shorter regulatory review periods. Gedatolisib previously received both Breakthrough Therapy and Fast Track designations based on p

    11/17/25 4:05:00 PM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Presented detailed efficacy and safety results from the PIK3CA wild-type ("WT") cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Medical Oncology ("ESMO") Congress Presented updated clinical results from the Phase 1b portion of a clinical trial evaluating gedatolisib in combination with Nubeqa® (darolutamide) in men with metastatic castration resistant prostate cancer ("mCRPC") at a poster session at ESMO Completed enrollment of the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial and expect topline data to be available sometime in late Q1 2026 or during Q2 2026 Submission of a New Drug Application ("NDA") t

    11/12/25 4:01:00 PM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

    MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, November 12, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this webli

    11/5/25 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Celcuity with a new price target

    Wolfe Research initiated coverage of Celcuity with a rating of Outperform and set a new price target of $110.00

    11/18/25 8:21:08 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Celcuity from Buy to Neutral

    11/17/25 9:39:18 AM ET
    $CELC
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Celcuity with a new price target

    Guggenheim initiated coverage of Celcuity with a rating of Buy and set a new price target of $110.00

    9/22/25 8:29:54 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Buller Richard E gifted 500 shares, exercised 3,900 shares at a strike of $14.83 and sold $377,255 worth of shares (3,900 units at $96.73) (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    11/21/25 4:14:32 PM ET
    $CELC
    Medical Specialities
    Health Care

    Director Nigon Richard exercised 7,917 in-the-money shares at a strike of $7.56, increasing direct ownership by 8% to 109,010 units (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    9/15/25 4:12:26 PM ET
    $CELC
    Medical Specialities
    Health Care

    Large owner Baker Bros. Advisors Lp bought $9,571,319 worth of shares (170,100 units at $56.27) (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    9/10/25 4:06:15 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Baker Bros. Advisors Lp bought $9,571,319 worth of shares (170,100 units at $56.27) (SEC Form 4)

    4 - Celcuity Inc. (0001603454) (Issuer)

    9/10/25 4:06:15 PM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Financials

    Live finance-specific insights

    View All

    Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call

    MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, November 12, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this webli

    11/5/25 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer

    Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ("gedatolisib triplet") and in 11.5% of patients treated with gedatolisib + fulvestrant ("gedatolisib doublet")Study treatment discontinuation due to treatment related adverse events was reported in 2.3% of patients treated with the gedatolisib triplet and 3.1% of patients with the gedatolisib doubletManagement to host webcast and conference call October 20, 2025, at 8:00 a.m. ET MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing

    10/18/25 4:30:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

    MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink:

    8/7/25 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Leadership Updates

    Live Leadership Updates

    View All

    Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

    Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

    7/8/25 10:25:00 AM ET
    $CELC
    $CTOR
    $EXEL
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Celcuity Appoints Eldon Mayer as Chief Commercial Officer

    MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology. "Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company's first drug. His significant commercial experience at multiple bio

    2/20/24 7:05:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors

    Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity's Board of DirectorsMINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced the appointment of Polly Murphy, D.V.M., Ph.D. to its Board of Directors."We are delighted to welcome Dr. Murphy to our Board and look forward to leveraging her business development expertise and broad industry experience as we continue to advance our pipeline," said Brian Sullivan, CEO and Co-Founder of Celcuity.Dr. Murphy joins Cel

    9/14/22 9:00:00 AM ET
    $CELC
    Medical Specialities
    Health Care

    $CELC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

    SC 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/24 5:46:12 PM ET
    $CELC
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

    SC 13G/A - Celcuity Inc. (0001603454) (Subject)

    11/14/24 5:46:16 PM ET
    $CELC
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Celcuity Inc.

    SC 13G - Celcuity Inc. (0001603454) (Subject)

    11/14/24 4:26:12 PM ET
    $CELC
    Medical Specialities
    Health Care